Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor

Transplantation

Volumn 81, Issue 6, 2006, Pages 949-952

  Pallet, Nicolas ^a   Anglicheau, Dany ^a   Martinez, Frank ^a   Mamzer, Marie France ^a   Legendre, Christophe ^a   Thervet, Eric ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Expanded criteria donor; Mycophenolate mofetil; Renal transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 33645638198     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000198417.91135.1f     Document Type: Article

References (17)

1. Canafax DM, Torres A, Fryd DS, et al. The effect of delayed graft function on recipients of cadaver renal allograft. Transplantation 1986; 41: 177.
2. McLaren AJ, Jassem W, Gray DW, et al. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long term survival in cadaveric renal transplantation. Clin transplant 1999; 13: 266.
3. Leunissen KML, Bosman FT, Nieman FH, et al. Amplification of the nephrotoxic effect of ciclosporine by preexistent chronic histological lesion in the kidney. Transplantation 1989; 48: 590.
4. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
5. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
6. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
7. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients; U.S. Renal transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60(15): 225.
8. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276.
9. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78(4): 584.
10. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
11. Ojo A, Sablinsky T, Roberts JP, et al. Prospectively validated scoring index to predict delayed graft function (DGF) in cadaveric renal transplantation. Am J Transplant 2002; 2(Suppl 3): 275.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
13. De Sévaux RGL, Gregoor PJH, Hene R, et al. A controlled trial comparing two doses of ciclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 2001; 12: 1750.
14. Troppmann C, Gillingham KJ, Gruessner RW, et al. Delayed graft function in the absence of rejection hs no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation 1996; 61(9): 1331.
15. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 63.
16. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998; 65: 248.
17. Knoll AG, Macdonald I, Khan A, Van Walraven K. Mycophenolate mophetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.